[go: up one dir, main page]

Daëron et al., 1980 - Google Patents

Mast cell membrane antigens and Fc receptors in anaphylaxis: II. Functionally distinct receptors for IgG and for IgE on mouse mast cells

Daëron et al., 1980

Document ID
8313919135252223220
Author
Daëron M
Prouvost-Danon A
Voisin G
Publication year
Publication venue
Cellular immunology

External Links

Snippet

The present work was aimed at analyzing the functional relationships between mouse mast cell receptors for IgG and IgE antibodies. It was based on a study of the inhibition of IgG1- and IgE-induced passive mast cell degranulation produced by various immunoglobulin …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
    • A61K47/4833—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Similar Documents

Publication Publication Date Title
Daëron et al. Mast cell membrane antigens and Fc receptors in anaphylaxis: II. Functionally distinct receptors for IgG and for IgE on mouse mast cells
Gosselin et al. Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens
Uhr et al. Delayed hypersensitivity: III. Specific desensitization of guinea pigs sensitized to protein antigens
Mitchison The carrier effect in the secondary response to hapten‐protein conjugates. V. Use of antilymphocyte serum to deplete animals of helper cells
Askenase et al. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses.
Raff et al. Early production of intracellular IgM by B-lymphocyte precursors in mouse
Benjamin et al. Mechanisms of monoclonal antibody‐facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA‐1) molecules in self‐non‐self discrimination
Ishizaka et al. A new concept of triggering mechanisms of IgE-mediated histamine release
US6649165B2 (en) Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using soluble FcγRIII receptors
AU613585B2 (en) Immunotoxin therapy of allergy
Ishizaka et al. Demonstration of Fcγ receptors on human basophil granulocytes
EP0585224A4 (en) Monoclonal antibodies which bind to secreted and membrane-bound ige, but not to ige on basophils
Muckerheide et al. Immunosuppressive properties of a peptic fragment of BSA
Haak-Frendscho et al. Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo
Borel et al. Selective suppression of delayed hypersensitivity by the induction of immunologic tolerance
JP2001501579A (en) Production of antibodies and medical uses involving antibodies
US20040047862A1 (en) Method for treating thrombocytopenia with monoclonal ivig
US5626844A (en) Monoclonal antibody against ricin A chain
James et al. The effect of anti-lymphocytic antibody on the humoral immune response in different strains of mice: I. The response to bovine serum albumin
Warren et al. Antigen mediation of a late-acting suppressor T-cell activity.
US6638506B1 (en) Method of blocking cytotoxic activity in patients with amyotrophic lateral sclerosis using antibodies to FcγRIII
Henriksen et al. Mitogenic effect on human lymphocytes of insolubilized anti-immunoglobulins. I. Specificity of the stimulating agent.
WO1991008773A1 (en) Tolerogenic immunoglobulin-protein conjugates
Kaliss et al. Immunological enhancement of a murine tumor allograft by passive alloantibody IgG and F (ab′) 2
Lang et al. Production of goat, rat, and guinea pig antisera to murine IgE